Alzai Health Corp. has satisfied all final listing requirements for the TSX Venture Exchange, paving the way for its shares to trade publicly following the completion of an initial public offering. The company, which provides an AI-driven risk screening solution for Alzheimer's Disease, anticipates that its common shares will commence trading under the symbol ALZI on June 9, 2026. This milestone is contingent on the closing of the offering, which aims to raise between $3,200,000 and $4,000,000 through the sale of units priced at $0.40 each.

The offering consists of a minimum of 8,000,000 units and a maximum of 10,000,000 units. Each unit comprises one common share and one-half of one common share purchase warrant. Each whole warrant entitles the holder to purchase one common share at an exercise price of $0.60 until June 9, 2028, subject to acceleration provisions. If the volume-weighted average trading price of the common shares reaches $0.90 for 10 consecutive trading days, the company may accelerate the warrant expiry to 30 days from the notice date.

Haywood Securities Inc. is acting as the exclusive agent for the offering on a best efforts basis. The agent has been granted an option to sell up to an additional 15% of the units sold under the offering to cover over-allotments. As compensation, Haywood Securities will receive a cash commission of 7% of the proceeds, agent's warrants equal to 7% of the total units issued, and a corporate finance fee of $45,000, payable in cash and common shares.

Offering Details

The company expects the common shares to be listed with an immediate trading halt effective at the close of markets on June 8, 2026. The TSXV is expected to issue a bulletin on June 9, 2026, announcing the lifting of the trading halt, after which shares will begin trading. Alzai Health focuses on early identification of cognitive decline using pre-existing patient data from routine clinical records.